KAT681 Inhibitor

98%

Powder: -2 degree C for 3 years
In solvent: -80 degree C for 2 years

463.437

[NaH].Cc1cc(NC(=O)CC(O)=O)cc(C)c1Oc1ccc(O)c(c1)C(O)c1ccc(F)cc1

C24H23FNNaO6

373641-87-3

Thyroid hormone receptor(THR)

(<1mg/mL refers to the product slightly soluble or insoluble)

KAT681 treatment causes a 60% decrease in plasma cholesterol and a 70% decrease in plasma triglycerides[1]. KAT681 obviously enhances hepatic LDLrs in SR-BI KO mice (2-fold of controls, P<0.01), along with a marked decrease in plasma cholesterol[2]. A marked decrease of plasma cholesterol is observed at 36nMoles/kg/day KAT681 (T-0681), whereas doses higher than 36nMoles/kg/day display no further lipid-lowering effect, in preliminary dose-titration studies. A marked increase of hepatic SR-BI expression at 36nMol/kg/d KAT681 (T-0681) and a concomitant 50% decrease of plasma cholesterol are observed, in preliminary dose-titration studies in wild-type (WT) mice. New Zealand White (NZW) rabbits are fed a 0.2% cholesterol diet and dosed with 36nMoles/kg/day KAT681 or respective placebo control for 4 weeks, in the subsequent study. Higher doses than 36nMol/kg/d display no further lipid-lowering effect.